Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized withdrawal and long-term extension study of ampreloxetine in multiple system atrophy with symptomatic neurogenic orthostatic hypotension
2023-504876-12-00Phase 3Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH) (3 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Change in OHSA composite score. Started Oct 2023; status: completed.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2023-504876-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504876-12-00.